Elysium Health Creates a New Kind of Supplement

Over the existence of the nutritional supplement industry, there have been many instances when products fell woefully short of consumer expectations. Some of these products could be described as outright scams. This has engendered a general lack of trust in the public towards the nutraceutical industry and has been a recurring problem for those companies operating within the $30 billion business that really want to make a difference through quality products.

Now Elysium Health, a company founded in 2014 by the MIT research scientist Dr. Leonard Guarente, is seeking to change the negative perception that the industry has garnered. Through the use of rigorous, science-based methods, Elysium is one of the first consumer health companies with genuinely stringent, self-imposed protocols that are designed to ensure the creation of top-quality products.

Currently, Elysium Health sells a supplement known as Basis. This supplement is designed to increase levels of NAD+ in our bodies. NAD+ is an essential coenzyme to many of our cellular functions like DNA protection and energy creation. As we age, the levels of this coenzyme decline and those functions break down. But Basis keeps our NAD+ levels high, supporting those functions and our cellular well-being as a result.

Basis undergoes strict third-party quality testing. The supplement has also been clinically tested and proven to increase levels of NAD+ by an average of 40 percent in humans.

Basis is available for purchase on Elysium Health’s website. Each jar of Basis contains a 30-day supply of the supplement. An individual jar costs $60, but monthly subscriptions to Basis decrease the cost to between $40 and $50 per jar, depending on the length of the subscription.

Under Dr. Guarente’s leadership, Elysium Health has a bright future. The company is developing new products that focus on cognitive health, skin health, muscle function, and circadian rhythms. These products are in various stages of pre-clinical and clinical trials.